卡非佐米及其组合药物在治疗多发性骨髓瘤的有效性及安全性分析

doi:10.5246/jcps.2017.03.023

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (3): 222-229.DOI: 10.5246/jcps.2017.03.023

卡非佐米及其组合药物在治疗多发性骨髓瘤的有效性及安全性分析

张林^1*, 金晓宣², 黄淑婷², 徐雯宇¹, 丁洁卫¹

1. 绍兴市人民医院浙江大学绍兴医院临床药学科, 浙江绍兴 312000
2. 绍兴文理学院化学化工学院药学系, 浙江绍兴 312000

收稿日期:2017-01-12 修回日期:2017-02-18 出版日期:2017-03-30 发布日期:2017-03-10
通讯作者: Tel.: +86-18258035799, +86-0575-88228650, E-mail: zl9099@126.com
基金资助:
Zhejiang Public Welfare Technology Application Research Project (Grant No. 2015C33285), Zhejiang Provincial Natural Science Foundation Project (Grant No. Y14H300005).

Analysis of the efficacy and safety of carfilzomib and its combination in multiple myeloma

Lin Zhang^1*, Xiaoxuan Jin², Shuting Huang², Wenyu Xu1, Jiewei Ding¹

1. Department of Pharmacy, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 31200, Zhejiang, China
2. School of Pharmacy, College of Chemistry and Chemical Engineering, Shaoxing University, Shaoxing 31200, Zhejiang, China

Received:2017-01-12 Revised:2017-02-18 Online:2017-03-30 Published:2017-03-10
Contact: Tel.: +86-18258035799, +86-0575-88228650, E-mail: zl9099@126.com
Supported by:
Zhejiang Public Welfare Technology Application Research Project (Grant No. 2015C33285), Zhejiang Provincial Natural Science Foundation Project (Grant No. Y14H300005).

摘要/Abstract

摘要：

卡非佐米在2012年被美国FDA批准成为治疗多发性骨髓瘤的新药后,随即成为了多发性骨髓瘤患者的一种新选择。但是关于卡非佐米及其组合物在治疗多发性骨髓瘤的临床效果没有很好的结论, 因此我们收集现有的临床试验报告分析卡非佐米在临床应用上的效果, 更好的说明该药的安全性与有效性, 并试图寻求卡非佐米更佳的治疗方案。检索数据库包括cochrane、EMBASE、PubMed、Medline、中国知识资源总库CNKI、万方数据库等国内外数据库; 检索关键字为: “Carfilzomib”, “Multiple myeloma”, “bortezomib”, “卡非佐米”, “多发性骨髓瘤”和 “硼替佐米”。最后应用R软件对收集到的数据进行META分析, 根据文章间的异质性决定使用固定效应模型或者随机效应模型。我们总共收集到了符合标准的文献总共17篇, 总计1960名多发性骨髓瘤患者参与试验。卡非佐米单药使用临床试验中总计多发性骨髓瘤患者594名, 总缓解率为32% (I² = 84.9%, P<0.0001); 在10组卡非佐米联合使用的临床试验共计1366名多发性骨髓瘤患者, 其中有1081名患者的治疗效果至少达到了PR (部分缓解), 总缓解率为79% (I² = 91.0%, P<0.0001)。不良反应多为发热、恶心、呕吐等非血液学事件, 其中周围神经性病变的发生率较硼替佐米有明显的改善。我们发现卡非佐米较硼替佐米耐受性好, 其周围神经病变发生概率较小, 治疗效果好, 不受其他药物的影响。在本次分析中得出, 卡非佐米, 来那度胺和地塞米松联合使用的总缓解率最高, 卡非佐米单药使用总缓解率较差且不良反应发生率较多。由此使用卡非佐米, 来那度胺和地塞米松组合物作为治疗药物有较满意的临床效果，但不过该结论尚待将来更多实验数据的支持。

关键词: 卡非佐米, 多发性骨髓瘤, META分析

Abstract:

Carfilzomib has become a new choice for patients with multiple myeloma (MM). However, the use of carfilzomib single-agent or in combination with other agents in MM patients is not explicitly clarified in clinical practice. Therefore, we analyzed the effects of carfilzomib and its safety and effectiveness using available clinical trial reports in order to find out the best therapy of carfilzomib. We searched MEDLINE, Embase, PubMed and Cochrane databases as well as Chinese databases of carfilzomib trials (Jan. 2012 to Sep. 2016) for the MM treatment. Clinical characteristics and outcomes were extracted. Meta-analysis results were expressed as the overall response rate (ORR) and performed by R software. A fixed-effects model or random-effects model was applied based on the heterogeneity among studies. Based on our research standard, we identified 17 prospective studies enrolling 1960 patients. A total of 594 MM patients were enrolled in carfilzomib single-agent clinical trials, and the ORR was 32% (I² = 84.9%, P<0.0001). A total of 1366 MM patients were enrolled in clinical trials of 10 groups of carfilzomib combination regimens, 1081 patients had a therapeutic effect, and the ORR was 79% (I² = 91.0%, P<0.0001). The most frequent adverse events were fever, nausea, vomiting and other non-hematologic events. Carfilzomib was better tolerated than bortezomib, with a lower incidence of peripheral neuropathy and better therapeutic effects compared with other drugs. In this analysis, the highest ORR was achieved from combination of carfilzomib, lenalidomide and dexamethasone, which had a lower incidence of adverse events and a greater ORR compared with carfilzomib single-agent. Therefore, the combination of carfilzomib, lenalidomide and dexamethasone could be a good therapeutic agent with strong clinical effect. However, this conclusion needs to be validated in future study.

Key words: Carfilzomib, Multiple myeloma, Meta-analysis

中图分类号:

R969

Supporting:

张林, 金晓宣, 黄淑婷, 徐雯宇, 丁洁卫. 卡非佐米及其组合药物在治疗多发性骨髓瘤的有效性及安全性分析[J]. 中国药学(英文版), 2017, 26(3): 222-229.

Lin Zhang, Xiaoxuan Jin, Shuting Huang, Wenyu Xu, Jiewei Ding. Analysis of the efficacy and safety of carfilzomib and its combination in multiple myeloma[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(3): 222-229.

参考文献

[1] Shank, B.R.; Brown, V.T.; Schwartz, R.N. J. Oncol. Pharm. Pract. 2015, 21, 36-51.

[3] Jain, S.; Diefenbach, C.; Zain, J.; O'Connor, O.A. Core Evidence. 2011, 6, 43-57.

[4] Nooka, A.; Gleason, C.; Casbourne, D.; Lonial, S. Biologics. 2013, 7, 13-32.

[5] Accardi, F.; Toscani, D.; Bolzoni, M.; Dalla Palma, B.; Aversa, F.; Giuliani, N. BioMed. Res. International. 2015, 172458.

[6] McBride, A.; Klaus, J.O.; Stockerl-Goldstein, K. Am J. Health Syst. Pharm. 2015, 72, 353-360.

[7] Grandin, E.W.; Ky, B.; Cornell, R.F.; Carver, J.; Lenihan, D.J. J. Cardiac Failure. 2015, 21, 138-144.

[8] Zou, Y.; Ma, X.; Yu, H.; Hu, C.; Fan, L.; Ran, X. Oncotarget. 2016, 5. doi: 10.18632/oncotarget.10768.

[9] Afanasyeva, M.A.; Britanova, L.V.; Korneev, K.V.; Mitkin, N.A.; Kuchmiy, A.A.; Kuprash, D.V. PloS one. 2014, 9, e98349.

[10] Zeng, Z.; Lin, J.; Chen, J. Ann. Hematol. 2013, 92, 935-943.

[11] Lendvai, N.; Hilden, P.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A.M.; Tsakos, I.; Redling, K.; Koehne, G.; Chung, D.J.; Schaffer, W.L.; Giralt, S.A. Blood. 2014, 124, 899-906.

[12] Jakubowiak, A.J.; Dytfeld, D.; Griffith, K.A.; Lebovic, D.; Vesole, D.H.; Jagannath, S.; Al-Zoubi, A.; Anderson, T.; Nordgren, B.; Detweiler-Short, K.; Stockerl-Goldstein, K.; Ahmed, A.; Jobkar, T.; Durecki, D.E.; McDonnell, K.; Mietzel, M.; Couriel, D.; Kaminski, M.; Vij, R. Blood. 2012, 120, 1801-1809.

[13] Vij, R.; Siegel, D.S.; Jagannath, S.; Jakubowiak, A.J.; Stewart, A.K.; McDonagh, K.; Bahlis, N.; Belch, A.; Kunkel, L.A.; Wear, S.; Wong, A.F.; Wang, M. British J. Haematology. 2012, 158, 739-748.

[14] Siegel, D.S.; Martin, T.; Wang, M.; Vij, R.; Jakubowiak, A.J.; Lonial, S.; Trudel, S.; Kukreti, V.; Bahlis, N.; Alsina, M.; Chanan-Khan, A.; Buadi, F.; Reu, F.J.; Somlo, G.; Zonder, J.; Song, K.; Stewart, A.K.; Stadtmauer, E.; Kunkel, L.; Wear, S.; Wong, A.F.; Orlowski, R.Z.; Jagannath, S. Blood. 2012, 120, 2817-2825.

[15] Aittasalo, M.; Raitanen, J.; Kinnunen, T.I.; Ojala, K.; Kolu, P.; Luoto, R. International J. Behavioral Nutrition Physical Activity. 2012, 9, 104.

[16] Berenson, J.R.; Hilger, J.D.; Yellin, O.; Dichmann, R.; Patel-Donnelly, D.; Boccia, R.V.; Bessudo, A.; Stampleman, L.; Gravenor, D.; Eshaghian, S.; Nassir, Y.; Swift, R.A.; Vescio, R.A. Leukemia. 2014, 28, 1529-1536.

[17] Watanabe, T.; Tobinai, K.; Matsumoto, M.; Suzuki, K.; Sunami, K.; Ishida, T.; Ando, K.; Chou, T.; Ozaki, S.; Taniwaki, M.; Uike, N.; Shibayama, H.; Hatake, K.; Izutsu, K.; Ishikawa, T.; Shumiya, Y.; Kashihara, T.; Iida, S.A. British J. Haematology. 2016, 172, 745-756.

[18] Papadopoulos, K.P.; Siegel, D.S.; Vesole, D.H.; Lee, P.; Rosen, S.T.; Zojwalla, N.; Holahan, J.R.; Lee, S.; Wang, Z.; Badros, A. J. Clin. Oncol. 2015, 33, 732-739.

[19] Dimopoulos, M.A.; Moreau, P.; Palumbo, A.; Joshua, D.; Pour, L.; Hájek, R.; Facon, T.; Ludwig, H.; Oriol, A.; Goldschmidt, H.; Rosiñol, L.; Straub, J.; Suvorov, A.; Araujo, C.; Rimashevskaya, E.; Pika, T.; Gaidano, G.; Weisel, K.; Goranova-Marinova, V.; Schwarer, A.; Minuk, L.; Masszi, T.; Karamanesht, I.; Offidani, M.; Hungria, V.; Spencer, A.; Orlowski, R.Z.; Gillenwater, H.H.; Mohamed, N.; Feng, S.; Chng, W.J. Lancet Oncol. 2016, 17, 27-38.

[20] Berdeja, J.G.; Hart, L.L.; Mace, J.R.; Arrowsmith, E.R.; Essell, J.H.; Owera, R.S.; Hainsworth, J.D.; Flinn, I.W. Haematologica. 2015, 100, 670-676.

[21] Wang, M.; Martin, T.; Bensinger, W.; Alsina, M.; Siegel, D.S.; Kavalerchik, E.; Huang, M.; Orlowski, R.Z.; Niesvizky, R. Blood. 2013, 122, 3122-3128.

[22] Stewart, A.K.; Rajkumar, S.V.; Dimopoulos, M.A.; Masszi, T.; Spicka, I.; Oriol, A.; Hajek, R.; Rosinol, L.; Siegel, D.S.; Mihaylov, G.G.; Goranova-Marinova, V.; Rajnics, P.; Suvorov, A.; Niesvizky, R.; Jakubowiak, A.J.; San-Miguel, J.F.; Ludwig, H.; Wang, M.; Maisnar, V.; Minarik, J.; Bensinger, W.I.; Mateos, M.V.; Ben-Yehuda, D.; Kukreti, V.; Zojwalla, N.; Tonda, M.E.; Yang, X.; Xing, B.; Moreau, P.; Palumbo, A.; Investigators, A. New England J. Med. 2015, 372, 142-152.

[23] Bringhen, S.; Petrucci, M.T.; Larocca, A.; Conticello, C.; Rossi, D.; Magarotto, V.; Musto, P.; Boccadifuoco, L.; Offidani, M.; Omedé, P.; Gentilini, F.; Ciccone, G.; Benevolo, G.; Genuardi, M.; Montefusco, V.; Oliva, S.; Caravita, T.; Tacchetti, P.; Boccadoro, M.; Sonneveld, P.; Palumbo, A. Blood. 2014, 124, 63-69.

[24] Moreau, P.; Kolb, B.; Attal, M.; Caillot, D.; Benboubker, L.; Tiab, M.; Touzeau, C.; Leleu, X.; Roussel, M.; Chaleteix, C.; Planche, L.; Chiffoleau, A.; Fortin, J.; Avet-Loiseau, H.; Mary, J.Y.; Hulin, C.; Facon, T. Blood. 2015, 125, 3100-3104.

[25] Shah, J.J.; Stadtmauer, E.A.; Abonour, R.; Cohen, A.D.; Bensinger, W.I.; Gasparetto, C.; Kaufman, J.L.; Lentzsch, S.; Vogl, D.T.; Gomes, C.L.; Pascucci, N.; Smith, D.D.; Orlowski, R.Z.; Durie, B.G.M. Blood. 2015, 126, 2284-2290.

[26] Sonneveld, P.; Asselbergs, E.; Zweegman, S.; van der Holt, B.; Kersten, M.J.; Vellenga, E.; van Marwijk-Kooy, M.; Broyl, A.; de Weerdt, O.; Lonergan, S.; Palumbo, A.; Lokhorst, H. Blood. 2015, 125, 449-456.

[27] Mikhael, J.R.; Reeder, C.B.; Libby, E.N.; Costa, L.J.; Bergsagel, P.L.; Buadi, F.; Mayo, A.; Nagi Reddy, S.K.; Gano, K.; Dueck, A.C.; Stewart, A.K. Br. J. Haematol. 2015, 169, 219-227.

[1]	张格第, 刘庚鑫, 晏子友. 基于meta分析和网络药理学理冲汤(丸)治疗癌症的疗效评价及作用机制研究[J]. 中国药学(英文版), 2023, 32(9): 720-735.
[2]	彭词艳, 陈景, 李斯妮, 李健和, 彭六保. 哌柏西利联用来曲唑对比多西他赛联用表柔比星一线治疗晚期乳腺癌的循证药物经济学评价[J]. 中国药学(英文版), 2023, 32(3): 214-222.
[3]	李雅静, 白雅雯, 杜宇, 严长宏, 麻春杰, 孙丽宁, 卜凤跃, 严昊阳. 玉屏风散治疗慢性肾小球肾炎的临床疗效评价及作用机制研究[J]. 中国药学(英文版), 2023, 32(12): 1006-1026.
[4]	李敏, 常路路, 岳向峰, 杜书章. ACEI联合丹参酮治疗肺心病急性加重期的疗效和安全性的meta分析[J]. 中国药学(英文版), 2022, 31(11): 853-865.
[5]	孙颖光, 岳圆圆, 邵杰敏, 高萌, 邓艳茹, 冯运佳. 康复新液与西瓜霜治疗复发性口腔溃疡疗效比较的meta分析[J]. 中国药学(英文版), 2022, 31(10): 761-772.
[6]	覃思蓓, 贾彤, 扶宇, 李俊蕾, 张欣怡, 祝春素, 梁广楷, 聂小燕, 史录文, 崔一民. CYP3A4基因多态性对心脑血管疾病患者氯吡格雷响应影响的Meta分析[J]. 中国药学(英文版), 2021, 30(9): 762-772.
[7]	周祎, 王军, 张龙. 他汀类药物对于COPD患者肺功能影响的荟萃分析[J]. 中国药学(英文版), 2018, 27(4): 281-288.
[8]	张林, 丁洁卫, 王阳, 金晓宣, 葛伟东, 黄淑婷, 李玉婷. 埃罗妥珠单抗治疗难治性/复发性多发性骨髓瘤临床试验效果的Meta分析[J]. 中国药学(英文版), 2017, 26(7): 528-533.
[9]	肖锐锐, 徐秀琴, 孙磊, 方晓磊, 肖鹏. 降心率药物伊伐布雷定安全性的系统评价[J]. 中国药学(英文版), 2017, 26(5): 379-389.
[10]	赵德华, 楚明明, 陈静, 王继生. 吉西他滨标准剂量30分钟快速输注与低剂量延时输注治疗进展期非小细胞肺癌的Meta分析[J]. 中国药学(英文版), 2017, 26(10): 763-770.
[11]	韩茹, 安雅晶, 赵荣生. α-酮酸对慢性肾脏病患者的附加作用: 一项随机对照试验的系统评价和meta分析[J]. 中国药学(英文版), 2017, 26(1): 63-75.
[12]	饶欣, 王长连, 许雄伟, 黄品芳, 王航, 林璐. 盐酸羟考酮缓释片与硫酸吗啡缓释片的临床疗效安全性对比[J]. 中国药学(英文版), 2016, 25(5): 387-394.
[13]	胡琴, 唐惠林, 邵宏. 基于肠促胰素药物治疗2型糖尿病合并非酒精性肝病的疗效和安全性的系统评价和meta分析[J]. 中国药学(英文版), 2016, 25(3): 206-214.
[14]	叶晓春, 董志, 赵春景, 李頔, 钱妍. 西尼地平与L-型钙离子通道阻滞剂对高血压患者肾脏功能影响的meta分析[J]. 中国药学(英文版), 2015, 24(11): 744-753.
[15]	季双敏, 尚德为, 王曦培, 李安宁, 任宇鹏, 李良, 周田彦, 王传跃, 卢炜. 基于meta分析的利培酮群体药代动力学研究及其在中国精神分裂症患者临床治疗药物监测中的预测应用[J]. 中国药学(英文版), 2014, 23(2): 75-82.

卡非佐米及其组合药物在治疗多发性骨髓瘤的有效性及安全性分析

Analysis of the efficacy and safety of carfilzomib and its combination in multiple myeloma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价